Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia.
作者信息
Thomas Simone, Schelker Roland, Klobuch Sebastian, Zaiss Sascha, Troppmann Martina, Rehli Michael, Haferlach Torsten, Herr Wolfgang, Reichle Albrecht
机构信息
Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg
Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg.
出版信息
Haematologica. 2015 Jan;100(1):e4-6. doi: 10.3324/haematol.2014.115055. Epub 2014 Sep 26.
Abstract
摘要
相似文献
1
Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia.
Haematologica. 2015 Jan;100(1):e4-6. doi: 10.3324/haematol.2014.115055. Epub 2014 Sep 26.
2
Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia.
Leukemia. 2020 Dec;34(12):3388-3392. doi: 10.1038/s41375-020-0973-z. Epub 2020 Jul 13.
3
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.
Leukemia. 2021 Mar;35(3):701-711. doi: 10.1038/s41375-020-0892-z. Epub 2020 Jun 19.
4
5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
Am J Hematol. 2013 Jul;88(7):601-5. doi: 10.1002/ajh.23464. Epub 2013 May 30.
5
Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
Leuk Res. 2020 Apr;91:106317. doi: 10.1016/j.leukres.2020.106317. Epub 2020 Feb 14.
6
Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia.
Ann Hematol. 2014 Dec;93(12):2081-2. doi: 10.1007/s00277-014-2119-8. Epub 2014 May 27.
7
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
Leuk Res. 2015 Mar;39(3):296-306. doi: 10.1016/j.leukres.2014.12.013. Epub 2014 Dec 31.
8
Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.
Anticancer Drugs. 2010 Apr;21(4):469. doi: 10.1097/CAD.0b013e328335be46.
9
A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
Leukemia. 2012 Nov;26(11):2428-31. doi: 10.1038/leu.2012.153. Epub 2012 Jun 5.
10
Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ann Hematol. 2019 Aug;98(8):1927-1932. doi: 10.1007/s00277-019-03719-6. Epub 2019 Jun 11.
引用本文的文献
1
Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance.
Cancers (Basel). 2023 Dec 29;16(1):180. doi: 10.3390/cancers16010180.
2
Low-dose azacitidine, pioglitazone and all- retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase.
Haematologica. 2024 Apr 1;109(4):1274-1278. doi: 10.3324/haematol.2023.283864.
3
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
Mol Genet Genomic Med. 2023 Mar;11(3):e2106. doi: 10.1002/mgg3.2106. Epub 2022 Nov 18.
4
Editorial: Anakoinosis for promoting tumor tissue editing: Novel therapeutic opportunities for establishing clinically relevant tumor control by targeting tumor plasticity.
Front Oncol. 2022 Sep 13;12:1005381. doi: 10.3389/fonc.2022.1005381. eCollection 2022.
5
Drug Repurposing by Tumor Tissue Editing.
Front Oncol. 2022 Jun 24;12:900985. doi: 10.3389/fonc.2022.900985. eCollection 2022.
6
A Proteomic Platform Enables to Test for AML Normalization .
Front Chem. 2022 Feb 1;10:826346. doi: 10.3389/fchem.2022.826346. eCollection 2022.
7
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.
Leukemia. 2021 Jul;35(7):1873-1889. doi: 10.1038/s41375-021-01218-0. Epub 2021 May 6.
8
A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung).
Front Pharmacol. 2021 Mar 16;12:599598. doi: 10.3389/fphar.2021.599598. eCollection 2021.
9
Deciphering Cancer Cell Behavior From Motility and Shape Features: Peer Prediction and Dynamic Selection to Support Cancer Diagnosis and Therapy.
Front Oncol. 2020 Oct 20;10:580698. doi: 10.3389/fonc.2020.580698. eCollection 2020.
10
Editorial: Tumor Systems Biology: How to Therapeutically Redirect Dysregulated Homeostasis in Tumor Systems (i.e., Anakoinosis).
Front Oncol. 2020 Sep 2;10:1675. doi: 10.3389/fonc.2020.01675. eCollection 2020.
本文引用的文献
1
Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas.
Oncoimmunology. 2013 Dec 1;2(12):e27058. doi: 10.4161/onci.27058. Epub 2013 Nov 5.
2
Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα.
Int J Cancer. 2014 Mar 1;134(5):1195-206. doi: 10.1002/ijc.28435. Epub 2013 Sep 3.
3
5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
Am J Hematol. 2013 Jul;88(7):601-5. doi: 10.1002/ajh.23464. Epub 2013 May 30.
4
Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.
Leukemia. 2013 Apr;27(5):1028-36. doi: 10.1038/leu.2012.312. Epub 2012 Nov 6.
5
CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling.
J Clin Invest. 2013 Jan;123(1):299-314. doi: 10.1172/JCI64745. Epub 2012 Dec 3.
6
All-trans retinoic acid combined with 5-Aza-2'-deoxycitidine induces C/EBPα expression and growth inhibition in MLL-AF9-positive leukemic cells.
Biochem Biophys Res Commun. 2012 Nov 16;428(2):216-23. doi: 10.1016/j.bbrc.2012.09.131. Epub 2012 Oct 10.
7
Effects of PPARγ Ligands on Leukemia.
PPAR Res. 2012;2012:483656. doi: 10.1155/2012/483656. Epub 2012 May 21.
8
Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment.
ScientificWorldJournal. 2012;2012:856467. doi: 10.1100/2012/856467. Epub 2012 Jan 4.
9
5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
Leukemia. 2012 Aug;26(8):1804-11. doi: 10.1038/leu.2012.47. Epub 2012 Feb 20.
10
Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.
Leuk Lymphoma. 2012 Jan;53(1):110-7. doi: 10.3109/10428194.2011.606382. Epub 2011 Aug 24.
Zotero 插件